Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 528403, 12 pages
http://dx.doi.org/10.1093/ecam/nep045
Original Article

Meta-Analysis of the Related Nutritional Supplements Dimethyl Sulfoxide and Methylsulfonylmethane in the Treatment of Osteoarthritis of the Knee

1Department of Primary Medical Care, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, Hampshire, SO16 5ST, UK
2School of Mathematics, University of Southampton, Southampton, Hampshire, SO16 5ST, UK

Received 24 October 2008; Accepted 23 April 2009

Copyright © 2011 Sarah Brien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Sangha, “Epidemiology of rheumatic diseases,” Rheumatology, vol. 39, supplement 2, pp. 3–12, 2000. View at Google Scholar · View at Scopus
  2. K. M. Jordan, N. K. Arden, M. Doherty et al., “EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies including Therapeutic Trials (ESCISIT),” Annals of the Rheumatic Diseases, vol. 62, pp. 1145–1155, 2003. View at Google Scholar
  3. D. T. Felson, R. C. Lawrence, M. C. Hochberg et al., “Osteoarthritis: new insights—part 2: treatment approaches,” Annals of Internal Medicine, vol. 133, no. 9, pp. 726–737, 2000. View at Google Scholar · View at Scopus
  4. R. W. Moskowitz, S. B. Abramson, and F. Berenbaum, “Coxibs and NSAIDs—clearing the air,” Osteoarthritis and Cartilage, vol. 13, no. 7, pp. 545–547, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Bjordal, A. E. Ljunggren, A. Klovning, and L. Slordal, “Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee: meta-analysis of randomised placebo controlled trials,” British Medical Journal, vol. 329, pp. 1317–1322, 2000. View at Google Scholar
  6. F. M. Arellano, “The withdrawal of rofecoxib,” Pharmacoepidemiology and Drug Safety, vol. 14, no. 3, pp. 213–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. D. M. Eisenberg, R. B. Davis, S. L. Ettner et al., “Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey,” Journal of the American Medical Association, vol. 280, no. 18, pp. 1569–1575, 1998. View at Google Scholar · View at Scopus
  8. J. K. Rao, K. Mihaliak, K. Kroenke, J. Bradley, W. M. Tierney, and M. Weinberger, “Use of complementary therapies for arthritis among patients of rheumatologists,” Annals of Internal Medicine, vol. 131, no. 6, pp. 409–416, 1999. View at Google Scholar · View at Scopus
  9. C. J. Herman, P. Allen, W. C. Hunt, A. Prasad, and T. J. Brady, “Use of complementary therapies amoung primary care clinic patients with arthritis,” Preventing Chronic Disease, vol. 1, pp. 1–15, 2004. View at Google Scholar
  10. C. L. Deal and R. W. Moskowittz, “Neutriceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondrotin sulphate and collagen hydrolysate,” Rheumatic Disease Clinics of North America, vol. 25, pp. 379–395, 1999. View at Google Scholar
  11. R. Bertken, ““Crystalline DMSO”: DMSO2,” Arthritis and Rheumatism, vol. 26, no. 5, pp. 693–694, 1983. View at Google Scholar · View at Scopus
  12. K. H. Kolb, G. Janicke, M. Kramer, and P. E. Schulze, “Adsorption, distribution and elimination of labeled DMSO in man and animal,” Annals of the New York Academy of Sciences, vol. 141, pp. 85–95, 1967. View at Google Scholar
  13. L. G. Ameye and W. S. S. Chee, “Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence,” Arthritis Research and Therapy, vol. 8, no. 4, article R127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. “Methylsulfonylmethane (MSM). Monograph,” Alternative Medicine Review, vol. 8, pp. 438–441, 2003.
  15. J. R. Cronin and K. Ballen, “The biochemistry of alternative therapies: methylsulfonylmethane: nutraceutical of the next century?” Alternative and Complementary Therapies, vol. 5, no. 6, pp. 386–389, 1999. View at Google Scholar · View at Scopus
  16. C. H. Demos, G. L. Beckloff, M. N. Donin, and P. M. Oliver, “Dimethyl sulfoxide in musculoskeletal disorders,” Annals of the New York Academy of Sciences, vol. 141, no. 1, pp. 517–523, 1967. View at Google Scholar · View at Scopus
  17. R. A. H. Jimenez and R. F. Willkens, “Dimethyl sulfoxide: a perspective of its use in rheumatic diseases,” Journal of Laboratory and Clinical Medicine, vol. 100, no. 4, pp. 489–500, 1982. View at Google Scholar · View at Scopus
  18. J. M. Trice and R. S. Pinals, “Dimethyl sulfoxide: a review of its use in the rheumatic disorders,” Seminars in Arthritis and Rheumatism, vol. 15, no. 1, pp. 45–60, 1985. View at Publisher · View at Google Scholar · View at Scopus
  19. E. D. Rosenstein, “Topical agents in the treatment of rheumatic disorders,” Rheumatic Disease Clinics of North America, vol. 25, no. 4, pp. 899–918, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ely and B. Lockwood, “What is the evidence for the safety and efficacy of dimethyl sulfoxide and methylsulfonylmethane in pain relief?” Pharmaceutical Journal, vol. 269, no. 7223, pp. 685–687, 2002. View at Google Scholar · View at Scopus
  21. S. Brien, P. Prescott, N. Bashir, H. Lewith, and G. Lewith, “Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis,” Osteoarthritis and Cartilage, vol. 16, no. 11, pp. 1277–1288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Evans, K. H. Reid, and J. B. Sharp, “Dimethyl sulphoxide blocks conduction in peripheral nerve C fibres: a possible mode of action,” Neuroscience Letters, vol. 150, pp. 145–148, 1993. View at Google Scholar
  23. M. Muir, “DMSO: many uses, much controversy,” Alternative and Complementary Therapies, vol. 2, pp. 230–235, 1996. View at Google Scholar
  24. S. W. Jacob and R. Herschler, “Dimethyl sulfoxide after twenty years,” Annals of the New York Academy of Sciences, vol. 411, pp. 14–18, 1983. View at Google Scholar · View at Scopus
  25. M. A. Beilke, C. Collins-Lech, and P. G. Sohnle, “Effects of dimethyl sulphoxide on the oxidative function of human neutraphils,” Journal of Laboratory and Clinical Medicine, vol. 110, pp. 91–96, 1987. View at Google Scholar
  26. H. E. Paulus, “FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma,” Arthritis and Rheumatism, vol. 29, no. 10, pp. 1289–1290, 1986. View at Google Scholar · View at Scopus
  27. I. Muravev, M. Venikova, G. N. Pleslovskaia, T. A. Riazantseva, and I. A. Sigidin, “Effect of dimethylsulphoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis,” Patologicheskaia Fiziologiia I Eksperimentalnaia Terapiia, vol. 2, pp. 37–39, 1991. View at Google Scholar
  28. C. F. Brayton, “Dimethyl sulfoxide (DMSO): a review,” The Cornell Veterinarian, vol. 76, no. 1, pp. 61–90, 1986. View at Google Scholar · View at Scopus
  29. K. Ebisuzaki, “Asprin and methylsulphonylmethane (MSM): a search for common mechanisms, with implictions for cancer prevention,” Anticancer Research, vol. 23, pp. 453–458, 2003. View at Google Scholar
  30. S. S. Alam and D. L. Layman, “Dimethyl sulphoxide inhibition of prostacylin production in culture aortic endothelial cells,” Annals of the New York Academy of Sciences, vol. 411, pp. 318–320, 1983. View at Google Scholar
  31. R. B. Fox and W. K. Fox, “Dimethyl sulphoxide prevents hydroxyl radical mediated depolymerisation of hyaluronic acid,” Annals of the New York Academy of Sciences, vol. 411, pp. 13–17, 1983. View at Google Scholar
  32. J. Morton and R. Moore, “Lupus nephritis and deaths are diminished in B/W mice drinking 3% water solution of dimethyl sulphoxide or dimethyl sulfone,” Journal of Leukocyte Biology, vol. 40, p. 322, 1986. View at Google Scholar
  33. T. Hasegawa, S. Ueno, S. Kumamoto, and Y. Yoshikai, “Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice,” Japanese Pharmacology and Therapeutics, vol. 32, no. 7, pp. 421–427, 2004. View at Google Scholar · View at Scopus
  34. R. Rizzo, M. Grandolfo, C. Godeas, K. W. Jones, and F. Vittur, “Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study,” Journal of Experimental Zoology, vol. 273, no. 1, pp. 82–86, 1995. View at Google Scholar · View at Scopus
  35. S. Parcell, “Sulfur in human nutrition and applications in medicine,” Alternative Medicine Review, vol. 7, no. 1, pp. 22–44, 2002. View at Google Scholar · View at Scopus
  36. A. A. Bookman, S. Williams, and J. Z. Shainhouse, “Effects of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial,” The Canadian Medical Association Journal, vol. 171, pp. 333–338, 2004. View at Google Scholar
  37. J. H. Brown, “Clinical experience with DMSO in acute musculoskeletal conditions comparing a noncontrolled series with a controlled double blind study,” Annals of the New York Academy of Sciences, vol. 141, no. 1, pp. 496–505, 1967. View at Google Scholar · View at Scopus
  38. K. H. Kolb, G. Jaenicke, M. Kramer, and P. E. Schulze, “Absorption, distribution and elimination of labeled dimethyl sulfoxide in man and animals,” Annals of the New York Academy of Sciences, vol. 141, no. 1, pp. 85–95, 1967. View at Google Scholar · View at Scopus
  39. U. Vuopala, H. Isomäki, and W. J. Kaipainen, “Dimethyl sulfoxide (DMSO) ointment in the treatment of rheumatoid arthritis. A double blind study,” Acta Rheumatologica Scandinavica, vol. 15, no. 2, pp. 139–144, 1969. View at Google Scholar · View at Scopus
  40. Micromedex Health Care Series, Micromedex Inc., Englewood, Colo, USA, 2008, http://lrs.lendac.ie/guides/micromedex/micromedex.html.
  41. Natural Medicine Comprehensive Database, Therapeutic Research Faculty, Stockton, Calif, USA, 5th edition, 2003.
  42. P. R. Usha and M. U. R. Naidu, “Randomised double blind, parallel, placebo controlled study of oral glucosamine, methylsulfonymethane and their combination in osteoarthritis,” Clinical Drug Investigation, vol. 24, pp. 353–363, 2004. View at Google Scholar
  43. L. S. Kim, L. J. Axelrod, P. Howard, N. Buratovich, and R. F. Waters, “Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial,” Osteoarthritis and Cartilage, vol. 14, no. 3, pp. 286–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Jacobs, R. M. Lawrence, and M. Siegel, Miracle MSM: The Natural Solution for Pain, GP Putnam, New York, NY, USA, 1999.
  45. Patent Storm, September 2008, http://www.patentstorm.us/patents/6399093/description.html.
  46. B. A. Magnuson, J. Appleton, and G. B. Ames, “Pharmacokinetics and distribution of [35S]methylsulfonylmethane following oral administration to rats,” Journal of Agricultural and Food Chemistry, vol. 55, no. 3, pp. 1033–1038, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Otsuki, W. Qian, A. Ishihara, and T. Kabe, “Elucidation of dimethylsulfone metabolism in rat using a S35 radioisotope tracer method,” Nutrition Research, vol. 22, no. 3, pp. 313–322, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Horváth, P. E. Noker, S. Somfai-Relle, R. Glávits, I. Financsek, and A. G. Schauss, “Toxicity of methylsulfonylmethane in rats,” Food and Chemical Toxicology, vol. 40, no. 10, pp. 1459–1462, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. B. A. Magnuson, J. Appleton, B. Ryan, and R. A. Matulka, “Oral developmental toxicity study of methylsulfonylmethane in rats,” Food and Chemical Toxicology, vol. 45, no. 6, pp. 977–984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. MSM Guide, September 2008, http://www.msmguide.com/facts/safety.
  51. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Bellamy, W. W. Buchanan, C. H. Goldsmith, J. Campbell, and L. W. Stitt, “Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee,” Journal of Rheumatology, vol. 15, no. 12, pp. 1833–1840, 1988. View at Google Scholar · View at Scopus
  53. D. Follmann, P. Elliott, I. Suh, and J. Cutler, “Variance imputation for overviews of clinical trials with continuous response,” Journal of Clinical Epidemiology, vol. 45, no. 7, pp. 769–773, 1992. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Cohen, Statistical Power Analysis for Behavioural Sciences, Lawrence Erlbaum, Hillsdale, NJ, USA, 2nd edition, 1988.
  55. N. J. Koenen, R. F. Haag, P. Bia, and P. Rose, “Perkutane therapie bei aktivierter Gonarthrose,” Münchener Medizinische Wochenschrift, vol. 138, pp. 534–538, 1996. View at Google Scholar
  56. R. Eberhardt, T. Zwingers, and R. Hofmann, “DMSO bei Patienten mit aktivierter Gonathrose. Eine doppeblinde, plazebokontrollierte Phase III Studie,” Fortschritte der Medizin, vol. 113, pp. 446–450, 1995. View at Google Scholar
  57. S. H. Roth and J. Z. Shainhouse, “Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial,” Archives of Internal Medicine, vol. 164, no. 18, pp. 2017–2023, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Muravyev, Y. Sigidin, and A. Alyabyeva, “A multicentre study of the effectiveness of dimethyl sulphoxide in rheumatoid and degenerative arthritis,” Terapevticheskii Arkhiv, vol. 59, pp. 106–108, 1987. View at Google Scholar
  59. N. M. R. Thie, N. G. Prasad, and P. W. Major, “Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial,” Journal of Rheumatology, vol. 28, no. 6, pp. 1347–1355, 2001. View at Google Scholar · View at Scopus
  60. A. M. Wood, I. R. White, and S. G. Thompson, “Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals,” Clinical Trials, vol. 1, no. 4, pp. 368–376, 2004. View at Google Scholar · View at Scopus
  61. F. Tubach, P. Ravaud, G. Baron et al., “Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement,” Annals of the Rheumatic Diseases, vol. 64, no. 1, pp. 29–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Angst, A. Aeschlimann, and G. Stucki, “Smallest detectable and minimally clinically important differences of rehabilitation interventions with their implications for required sample sizes using WOMAC and SF36 Quality of life measurement instruments in patients with osteoarthritis of the lower extremities,” Arthritis Care's Research, vol. 45, pp. 384–391, 2001. View at Google Scholar
  63. E. W. Ehrich, G. M. Davies, D. J. Watson, J. A. Bolognese, B. C. Seidenberg, and N. Bellamy, “Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire and global assessments in patients with osteoarthritis,” Journal of Rheumatology, vol. 27, no. 11, pp. 2635–2641, 2000. View at Google Scholar · View at Scopus
  64. N. Bellamy, J. Kirwan, M. Boers et al., “Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III,” Journal of Rheumatology, vol. 24, no. 4, pp. 799–802, 1997. View at Google Scholar · View at Scopus
  65. P. Brooks, P. Tugwell, C. V. Strand, and L. Simon, “International consensus conference on outcome measures in rheumatology, gold coast Australia, April 11–14 2002,” The Journal of Rheumatology, vol. 30, pp. 866–867, 2003. View at Google Scholar
  66. G. P. Geba, A. L. Weaver, A. B. Polis, M. E. Dixon, and T. J. Schnitzer, “Efficacy of rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee: a randomised trial,” Journal of the American Medical Association, vol. 287, pp. 64–71, 2002. View at Google Scholar
  67. E. W. Ehrich, T. J. Schnitzer, H. Mcllwain et al., “Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebp controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group,” The Journal of Rheumatology, vol. 26, pp. 2438–2447, 1999. View at Google Scholar